Knowledge About the Human Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement by Dahlstrom, Kristina R et al.
Journal of Applied Research on Children: Informing Policy for 
Children at Risk 
Volume 10 
Issue 2 Vaccinations in Texas: Lessons Learned 
for Evidence-Based Practices for Child Health 
Article 5 
2019 
Knowledge About the Human Papillomavirus Vaccine Among 
Employees at a Tertiary Cancer Center: Room for Improvement 
Kristina R. Dahlstrom 
The University of Texas MD Anderson Cancer Center, kdahlstrom@mdanderson.org 
Erich M. Sturgis 
The University of Texas MD Anderson Cancer Center, esturgis@mdanderson.org 
Ronald A. DePinho 
The University of Texas MD Anderson Cancer Center, rdepinho@mdanderson.org 
Ernest Hawk 
The University of Texas MD Anderson Cancer Center, ehawk@mdanderson.org 
George P. Baum 
The University of Texas MD Anderson Cancer Center, gpbaum@mdanderson.org 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.library.tmc.edu/childrenatrisk 
Recommended Citation 
Dahlstrom, Kristina R.; Sturgis, Erich M.; DePinho, Ronald A.; Hawk, Ernest; Baum, George P.; Tamez, 
Elenita; Bello, Rosalind S.; Stevens, Lori D.; and Ramondetta, Lois M. (2019) "Knowledge About the Human 
Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement," Journal 
of Applied Research on Children: Informing Policy for Children at Risk: Vol. 10 : Iss. 2 , Article 5. 
Available at: https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/5 
The Journal of Applied Research on Children is brought 
to you for free and open access by CHILDREN AT RISK at 
DigitalCommons@The Texas Medical Center. It has a "cc 
by-nc-nd" Creative Commons license" (Attribution Non-
Commercial No Derivatives) For more information, please 
contact digitalcommons@exch.library.tmc.edu 
Knowledge About the Human Papillomavirus Vaccine Among Employees at a 
Tertiary Cancer Center: Room for Improvement 
Acknowledgements 
The authors wish to thank Stephanie Deming for manuscript editing. Funding: This research was 
supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support 
Grant [grant number CA016672]. This research was accomplished within the MD Anderson Cancer Center 
HPV-Related Cancers Moon Shot Program, the Stiefel Oropharyngeal Research Fund, which supports the 
MD Anderson Oropharynx Program, and the Christopher and Susan Damico Chair in Viral Associated 
Malignancies at The University of Texas MD Anderson Cancer Center. Conflicts of interest: Dr. Hawk 
reports non-financial relationships with Huntsman Cancer Institute, Kansas University Medical Center, 
Maya Clinic Cancer Center, Ohio State University, Roswell Park Cancer Institute, University of Nebraska 
Medical Center, UT Southwestern, American Cancer Society, University of Alabama Mitchell Cancer 
Institute, Johns Hopkins University, NCI, Oncology Nursing Society Conference, Weill Cornell Medical 
College, AACR, ASCO, Alliance Prevention Committee, John Wiley & Sons Ltd. 
Authors 
Kristina R. Dahlstrom, Erich M. Sturgis, Ronald A. DePinho, Ernest Hawk, George P. Baum, Elenita Tamez, 
Rosalind S. Bello, Lori D. Stevens, and Lois M. Ramondetta 
This original contribution is available in Journal of Applied Research on Children: Informing Policy for Children at Risk: 
https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/5 
  
Knowledge About the Human Papillomavirus Vaccine Among 
Employees at a Tertiary Cancer Center: Room for Improvement 
 
INTRODUCTION 
 
Human papillomavirus (HPV) is associated with substantial morbidity and 
mortality. HPV is the cause of virtually all cervical dysplasias and cancers 
as well as all cases of genital warts and most oropharyngeal, vaginal, 
vulvar, penile, and anal cancers. The HPV vaccine has been available since 
2006 and is recommended by the U.S. Centers for Disease Control and 
Prevention (CDC) for routine vaccination of boys and girls to protect against 
HPV-related cancers and genital warts.1,2 Population-level impact has 
already been observed in the United States and elsewhere in the form of 
decreased incidence of HPV-related diseases including cervical cancer 
attributed to vaccine-preventable HPV types (16 and 18).3-6 The Healthy 
People 2020 target for HPV vaccination is 80% coverage for both boys and 
girls7; however, HPV vaccine uptake has been low in the United States 
compared to other nations. In 2018, the most recent estimate available, 
44% of adolescents had completed the vaccine series in Texas.8 
Several studies have identified significant barriers to HPV 
vaccination among both health care providers and parents.9-12 A major 
barrier cited by parents is lack of a recommendation from a health care 
provider. In the 2018 National Immunization Survey–Teen (NIS-Teen), ≥1 
dose HPV vaccination coverage was only 47% among adolescents whose 
parents had not received a recommendation compared with 75% among 
adolescents whose parents had.8 Furthermore, receiving a provider 
recommendation varied by state (60%-91%) and has led the CDC to 
prioritize supporting providers to give a strong recommendation. Reasons a 
provider may be hesitant to recommend vaccination are lack of knowledge 
regarding association between HPV infection and non-cervical HPV-related 
cancers or genital warts, concerns regarding parents’ attitudes toward the 
vaccine, the financial impact for parents, and inadequate or slow 
reimbursement.9,10,13-15 Furthermore, some providers may have a 
preference for vaccinating older versus younger adolescents or girls versus 
boys. Among parents, insufficient knowledge about the vaccine in terms of 
safety and potential adverse events, belief that the child is too young, or 
that vaccinating could lead to promiscuity are additional barriers.9,11,14-16 
Unfortunately, lack of awareness that the vaccine is available and beneficial 
for males has been cited by both providers and parents as a reason for not 
vaccinating.9-11    
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To meet the Healthy People 2020 HPV vaccination target, it is 
imperative to provide parents with accurate information and ensure that 
health care providers are aware of the importance of strongly 
recommending the HPV vaccine to all eligible adolescents. The goal of this 
study was to determine the vaccination patterns and attitudes toward the 
HPV vaccine among employees at a tertiary cancer center in order to 
identify focus areas for education. We also sought to determine whether 
these differed with respect to health care provider status. The study was 
designed not only to gather information but also to be informative for 
employees as they are in a position to advocate for HPV vaccination to 
patients and the public. 
 
METHODS 
 
The study was conducted at an urban tertiary cancer center. All employees 
were invited to participate in an online survey through an institution-wide 
email from the institution’s president as well as an online employee news 
article that contained a link to the survey. In addition, division heads were 
encouraged to send reminder emails to all employees in their divisions, and 
a reminder was posted on the employee news webpage. The link to the 
survey was active for 2 weeks, from July 27, 2015, through August 10, 2015. 
The survey was administered using the online survey software Qualtrics 
(Provo, Utah) through the Office of Health Policy, and no incentive was 
offered. 
The anonymous survey (see Appendix) included questions about 
respondents’ health care provider status (health care provider or not) and 
health care provider classification (eg, physician, physician assistant, nurse 
practitioner, nurse, social worker). Respondents were also asked about 
their knowledge regarding HPV-vaccine insurance coverage as we wanted 
to clarify through survey question design that HPV vaccinations are covered 
by insurance and also covered for those who are uninsured. Respondents 
were asked whether they had completed the HPV vaccine series (3 doses 
at the time of the survey). Those who reported not having completed the 
series were given a list of potential reasons, including ineligibility due to age, 
and were asked to choose the main reason why they had not completed the 
series. An option to indicate “other” as the main reason and an option to 
provide a text comment were also provided. These responses were 
categorized by theme (eg,”1 partner” or “am in a committed relationship” 
were categorized together and “by the time I knew about it, I was too old” 
and “didn’t know about it until after I was 26” were categorized together).  
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Additionally, respondents were asked about their children’s 
vaccination history. If a respondent reported that a child had not completed 
the vaccine series, the respondent was given a list of potential reasons, 
including ineligibility due to age, and was asked to choose the main reason. 
An option to indicate “other” as the main reason and an option to provide a 
text comment were also provided. These responses were categorized as 
previously described. Respondents were asked about each of their children, 
and results are reported for each child. Respondents were also asked about 
intention to vaccinate young children in the future and interest in an 
institutional vaccination clinic for employees and their children. This study 
was considered exempt from review by the institutional review board due to 
the anonymous nature of the survey. 
 
Statistical analysis  
 
All statistical analyses were done using Stata 12.0 (StataCorp, College 
Station, Texas). All tests were 2-sided, and p<.05 was considered 
statistically significant. Standard descriptive statistics were used to describe 
the study population. Chi-square or Fisher’s exact test was used to 
determine whether differences between groups were statistically significant.  
 
RESULTS 
 
Characteristics of participants 
 
A total of 20,673 employees were invited to participate, and 4366 completed 
the survey (response rate, 21%; Table 1). Of the total employee population, 
50% of the faculty (862 of 1709) completed the survey, compared with 35% 
of students and trainees (449 of 1293) and only 17% of administrative and 
other staff (2970 of 17,671). The majority of respondents (64%) were non-
health care providers. Of the respondents who were health care providers, 
11% cared for pediatric patients at least 25% of the time. 
Knowledge about HPV vaccine insurance coverage 
 
While most respondents knew that the vaccine is covered under the 
Affordable Care Act (58% of respondents knew) and the Vaccines for 
Children program (57%), less than a quarter (21%) knew that it is covered 
under the Adult Safety Net program (Table 1). Health care providers were 
significantly more likely than non–health care providers to know that the 
vaccine is covered for most eligible individuals. 
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Table 1. Health care provider status and knowledge about HPV vaccine 
insurance coverage among employees responding to survey. 
   Health care provider status 
 
  
All 
N=4,366 
Health care 
provider 
N=1,548 
Non–health 
care provider 
N=2,787 
 
Survey question and 
responses N (%) N (%) N (%) p 
Health care provider 
classification 
    
 
Physician -- 403 (26.1) -- 
 
 
PA/NP -- 226 (14.7) -- 
 
   Nurse -- 480 (31.1) -- 
 
 
Social worker/case 
manager 
-- 425 (27.6) -- 
 
 
Other -- 8 (0.5) -- 
 
 Missing  6   
Care for pediatric 
patients ≥25% of time 
   
 
 No -- 1,369 (88.9) --  
 Yes -- 171 (11.1) --   
Missing 
 
8 
  
Sex 
   
.671  
Male 1,163 (26.8) 406 (26.4) 749 (27.0) 
 
 
Female 3,178 (73.2) 1,134 (73.6) 2,029 (73.0) 
 
 Missing 25 8 15  
Know that HPV vaccine 
is covered by ACA 
   <.001 
 
No 1,811 (41.8) 484 (31.7) 1,316 (47.4) 
 
 Yes 2,518 (58.2) 1,041 (68.3) 1,463 (52.6)  
 Missing 37 14 11  
Know that HPV vaccine 
is covered by VFC 
   <.001 
 
No 1,851 (42.7) 564 (36.7) 1,274 (45.9) 
 
 Yes 2,487 (57.3) 972 (63.3) 1,503 (54.1)  
 Missing 28 12 13  
Know that HPV vaccine 
is covered by ASN 
   <.001 
 No 3,439 (79.2) 1,151 (74.5) 2,268 (81.8)  
 Yes 905 (20.8) 394 (25.5) 506 (18.2)  
 Missing 22 5 20  
Italics indicates statistical significance (p<.05) 
HPV, human papillomavirus; PA/NP, physician assistant/nurse practitioner; ACA, 
Affordable Care Act; VFC, Vaccines for Children program; ASN, Adult Safety Net 
program. 
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Vaccination patterns 
 
Table 2 shows the vaccination patterns of respondents overall and by 
health care provider status. Approximately half of respondents either had 
completed the vaccine series or indicated that their reason for not being 
vaccinated was something other than age ineligibility; these respondents 
(52% of men and 48% of women) were assumed to have been eligible for 
HPV vaccination. Of those eligible, 13% (80/607) of men and 33% 
(499/1514) of women had completed the vaccine series. Among eligible 
individuals, the most common reason for not completing the series among 
both men and women was lack of knowledge that the vaccine was needed 
(51% for men and 27% for women). Very few respondents had safety 
concerns about the vaccine or did not feel they had enough information 
about the vaccine. The most common write-in reasons for not having 
completed the vaccine series were not being aware of the vaccine until over 
age 26 (N=30), already having been diagnosed with HPV infection (N=14), 
being in a monogamous relationship (N=31), and inconvenience (N=6). 
Among men eligible for the HPV vaccine, there was no difference in 
personal vaccination rates between health care providers and non–health 
care providers (p=.632). Likewise, reasons for not completing the vaccine 
series did not differ between these 2 groups (p=.126; Table 2). However, 
among women eligible for the vaccine, providers were significantly more 
likely than non-providers to have completed the 3-dose series (40% vs 30%; 
p<.001). In addition, among women, providers were significantly less likely 
than non-providers to cite not knowing they needed the vaccine (20% vs 
29%) or safety concerns (6% vs 7%) as the main reason for completing the 
vaccine series (Table 2). 
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Table 2. HPV vaccination patterns of employees responding to survey 
by sex and health care provider status.  
All Male Female 
  
 
Male 
N=1163 
 
Female 
N=3178 
Health 
care 
provider 
N=406 
Non–
health 
care 
provider 
N=749 
Health 
care 
provider 
N=1134 
Non–
health 
care 
provider 
N=2029 
  N (%) N (%) N (%) N (%) N (%) N (%) 
Completed the 
HPV vaccine 
series       
No 
527 
(86.8) 
1015 
(67.0) 
144 
(85.7) 
381 
(87.2) 
288 
(59.9) 
721 
(70.3) 
Yes 
80 
(13.2) 
499 
(33.0) 
24 
(14.3) 
56 
(12.8) 
193 
(40.1) 
304 
(29.7) 
Not eligible 547 1644 236 306 645 992 
Missing 9 20 2 6 8 12 
Reason for not 
completing if 
eligible       
Started but    
never finished 
3 
(0.6) 
50 
(5.0) 
2 
(1.4) 
1 
(0.3) 
23 
(8.1) 
27 
(3.8) 
Didn’t know it 
was needed 
262 
(50.6) 
269 
(26.8) 
66 
(46.5) 
196 
(52.4) 
57 
(20.1) 
210 
(29.4) 
Safety 
concerns 
16 
(3.1) 
69 
(6.9) 
6 
(4.2) 
10 
(2.7) 
16 
(5.6) 
52 
(7.3) 
Health care 
provider did not 
recommend it 
 
58 
(11.2) 
 
210 
(20.9) 
 
17 
(12.0) 
 
41 
(11.0) 
 
57 
(20.1) 
 
153 
(21.4) 
Don’t have 
enough 
information 
about the 
vaccine 
 
41 
(7.9) 
 
84 
(8.4) 
 
9 
(6.3) 
 
32 
(8.6) 
 
21 
(7.4) 
 
62 
(8.7) 
Not sexually 
active 
30 
(5.8) 
91 
(9.1) 
4 
(2.8) 
26 
(7.0) 
35 
(12.3) 
56 
(7.8) 
Didn’t know it 
was covered by 
my insurance 
 
24 
(4.6) 
 
35 
(3.5) 
 
9 
(6.3) 
 
15 
(4.0) 
 
9 
(3.2) 
 
25 
(3.5) 
Other 
84 
(16.2) 
195 
(19.4) 
29 
(20.4) 
53 
(14.2) 
66 
(23.2) 
129 
(18.1) 
Missing 9 12 2 7 4 7 
HPV, human papillomavirus. 
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Sixty-one percent of the respondents (N=2664) had children. Of 
2659 daughters, 2038 (77%) were eligible to be vaccinated, and of 2077 
sons, 1562 (75%) were eligible to be vaccinated (Table 3). Of the children 
who were eligible, 899 (44%) girls and 376 (24%) boys had completed the 
vaccine series. Children of providers were significantly more likely to have 
completed the vaccine series than were children of non-providers (boys, 
29% vs 22%, p=.001; girls, 48% vs 42%, p=.004). Reasons for not 
vaccinating children differed for boys and girls (Table 3 and Figure 1). 
Although not knowing that vaccination was needed was a common reason 
for not vaccinating both boys and girls, this reason was more common for 
boys than for girls, and providers were less likely to cite this reason than 
were non-providers. There was no difference in vaccine completion rates 
between households with both boys and girls and those with only boys or 
only girls (p=.892 and p=.991, respectively; data not shown). The majority 
of participants with children who were too young for vaccination were 
planning to have children vaccinated when they were old enough (boys, 
79%; girls, 82%); providers were significantly more likely than non-providers 
to indicate such plans (p=.010 for girls and p=.001 for boys; Table 3). 
Write-in reasons for not vaccinating children were child is 
developmentally disabled or autistic and unlikely to become sexually active 
(N=3), parent does not vaccinate children at all (N=2), pediatrician 
recommended waiting until child is older (N=3), parent believes that vaccine 
offers a false sense of security as it does not cover all high-risk HPV types 
(N=5), long-term side effects are unknown (N=9), doctor did not have 
vaccine available (N=2), getting all 3 doses is too much trouble (N=3), 
doctor refuses to give HPV vaccine as it is “not fully covered by insurance”  
(N=2), parent does not want government to be involved in health care 
decisions (N=4), and parent believes HPV-related cancers are rare and 
therefore vaccine is not warranted (N=1).  
In response to the question whether employees would be willing to 
bring their children to an immunization clinic if it were offered for employees 
on the institution’s campus on a weekend, 58% of respondents with children 
expressed an interest. 
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Table 3. HPV vaccination patterns of children of employees 
responding to survey by health care provider status.  
All Sons Daughters 
  
 
Sons 
N=2077 
 
Daughters 
N=2659 
Health 
care 
provider 
N=801 
Non–
health 
care 
provider 
N=1238 
Health 
care 
provider 
N=991 
Non–
health 
care 
provider 
N=1649 
  N (%) N (%) N (%) N (%) N (%) N (%) 
Completed the 
HPV vaccine 
series 
      
No 1186  
(75.9) 
1139 (5.9) 395 (71.3) 758  
(78.5) 
371 
(51.7) 
761 
(58.3) 
Yes 376  
(24.1) 
899 (44.1) 159 (28.7) 215  
(21.5) 
347 
(48.3) 
544 
(41.7) 
Not eligible 515 621 247 265 273 344 
Reason for 
not completing 
if eligible 
      
Started but 
never 
finished 
35  
(3.2) 
45  
(4.2) 
16  
(4.4) 
19  
(2.6) 
19  
(5.4) 
26  
(3.7) 
Didn’t know 
it was 
needed 
390  
(35.8) 
185 (17.3) 106 (29.0) 283  
(39.3) 
38  
(10.7) 
145 
(20.4) 
Safety 
concerns 
68  
(6.2) 
107 (10.0) 30  
(8.2) 
38  
(5.3) 
43  
(12.2) 
64  
(9.0) 
Health care 
provider did 
not 
recommend 
it 
 
218  
(20.0) 
 
149 (13.9) 
 
72  
(19.7) 
 
145  
(20.1) 
 
44  
(12.4) 
 
105 
(14.8) 
Don’t have 
enough 
information 
about the 
vaccine 
 
104  
(9.5) 
 
95  
(8.9) 
 
31 
 (8.5) 
 
71  
(9.9) 
 
30  
(8.5) 
 
65  
(9.1) 
Child not 
sexually 
active 
20  
(1.8) 
175 (16.4) 7  
(1.9) 
13  
(1.8) 
67  
(18.9) 
108 
(15.2) 
Didn’t know 
it was 
covered by 
my 
insurance 
 
1  
(0.1) 
 
21  
(2.0) 
 
1  
(0.3) 
 
0 
 
6  
(1.7) 
 
15  
(2.1) 
Other 255  
(23.4) 
293 (27.4) 103 (28.1) 151 
(21.0) 
107 
(30.2) 
184 
(25.8) 
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Missing 95 69 29 65 17 49 
If child too 
young, plan to 
vaccinate 
when old 
enough 
      
No 99  
(21.2) 
97  
(18.0) 
34  
(14.9) 
65  
(27.7) 
31  
(13.3) 
66  
(21.9) 
Yes 367  
(78.8) 
442 (82.0) 194 (85.1) 170  
(72.3) 
203 
(86.8) 
236 
(78.2) 
HPV, human papillomavirus. 
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Figure 1. Reasons given by employees for not vaccinating their 
eligible children against HPV. 
 
 
DISCUSSION 
 
In this survey study of employees at a tertiary cancer center, we found that 
the majority of eligible employees and employees’ eligible children had not 
completed the HPV vaccine series, and employees’ knowledge about the 
HPV vaccine was lacking. We were surprised by these findings in this group 
with such close contact with people with cancer. 
Only 44% of respondents’ eligible daughters and 24% of 
respondents’ eligible sons had completed the HPV vaccine series at the 
time the survey was conducted. These rates were approximately the same 
as the 2015 national and Texas-specific rates of 42% and 41%, 
respectively, for girls and 28% and 24%, respectively, for boys as well as 
approximately the same as rates for the city of Houston, Texas, where our 
institution is located (43% for girls and 23% for boys).17 The HPV 
vaccination rate among eligible employees was lower than that of 
employees’ children (13% of men and 33% of women). This appears to be 
due to, in part, a lack of information in the years immediately following 
vaccine introduction and a lack of a recommendation from a provider.      
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Our results are largely consistent with psychosocial barriers to HPV 
vaccination described previously, including knowledge of vaccine and 
recommendations, perceived benefits and susceptibility, perceived vaccine 
safety, and provider recommendation.18,19 Importantly, studies have 
consistently shown that one of the most important factors for parents in 
deciding to vaccinate is a strong recommendation from a health care 
provider.8,20,21 In our study, we found that 14% of respondents with vaccine-
eligible but unvaccinated daughters and 20% of respondents with vaccine-
eligible but unvaccinated sons cited lack of recommendation from a provider 
as the main reason for lack of vaccination. These findings regarding lack of 
recommendation from a provider agree with previously reported findings 
from a national survey.8 Unfortunately, some respondents reported that 
their provider had advised waiting until the child was older than 12 years 
even though the CDC recommendation is to vaccinate 11- and 12-year-
olds. In other cases, the provider did not have the vaccine available. 
Concerning insurance coverage and cost of the vaccine, some 
respondents reported that their provider did not offer the vaccine because 
it was not “fully covered by insurance.” These responses reflect provider 
lack of knowledge about the vaccine and insurance coverage; most eligible 
individuals in fact qualify to receive the HPV vaccine at no or low cost 
through the Affordable Care Act, Vaccines for Children program, or Adult 
Safety Net program. Many survey respondents, even providers, were 
unaware of this fact. Concerns about cost of vaccine have previously been 
reported in other U.S. surveys.9,19  
The low vaccination rate among employees themselves seems to be 
a reflection of being unaware of the vaccine or necessity for it as has been 
seen with providers and survivors regarding knowledge of effectiveness, 
timeliness, safety, and coverage and willingness to vaccinate or get family 
members vaccinated.22-24  In a Web-based survey of parents to 11- to 17-
year old males in the United States, more than half of parents reported not 
vaccinating their son because they did not have a recommendation from a 
provider; however, vaccine acceptability was high, indicating that 
vaccination uptake could be greatly increased with strong and consistent 
recommendations from providers.25  
What is discouraging about most published HPV intervention 
programs is that benefits of multimodality interventions involving the most 
effective interventions have limited change in vaccination rate of 9% to14% 
improvement after interventions were employed.26,27 And although it takes 
time to change societal beliefs and behaviors, new methods of “moving the 
dial” towards a pro-vaccine country are needed.28,29 This is especially true 
due to the strength of the anti-vax community as evidenced by the recent 
11
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threat made towards a pediatrician for an educational Tick Tock video or a 
practice.30,31 In a major cancer center where a significant number of HPV- 
related cancers are treated, and where there is strong support for HPV 
vaccination, our survey set out to explore if our employees were behind this 
mission to prevent further HPV-related cancers. What we found through this 
survey is that despite close contact with cancer patients, our employees, 
and even our survivors of HPV-related diseases, were no more educated or 
vaccinated than the general population.   
Workplace health promotion programs are encouraged by the 
CDC.32 Our institution is committed to improving the health of its employees 
and offers health promotion programs, including yearly flu vaccination 
programs, resources for smoking cessation and stress management, 
nutrition education, and a fitness center. As a result of this survey, HPV 
vaccination education can now be seen as a need for our employees, and 
our institution has been conducting an educational campaign on the benefits 
of HPV vaccination. The campaign currently includes online resources and 
informational talks at department meetings as well as posters and 
interactive educational materials available to employees, patients, and 
visitors throughout the campus.  
 
Limitations 
 
The main limitation of this study was the low response rate. We took 
measures to increase the response rate, such as having the president send 
an institution-wide email, having division heads send reminders, and 
placing a prominent article in the employee newsletter. Despite these 
efforts, only 21% of employees completed the survey. It is possible that only 
employees with strongly held beliefs, either for or against HPV vaccination, 
chose to respond. Furthermore, some employees may have thought that 
the survey did not pertain to them and thus did not respond. For example, 
in our own experiences talking with colleagues, we found that many male 
employees seemed surprised when they were verbally asked to take the 
survey, stating, “I thought this was only for girls” or something similar. The 
survey was available online, and it is possible that some groups of 
employees did not have online access. The response rate varied according 
to employee classification, with a higher proportion of faculty than of other 
employees responding. It is possible that reminder emails sent out by 
department heads were more likely to be sent to faculty than to all 
department employees. Finally, we did not ask for the age of respondents 
or their children, and we assumed that employees and children were eligible 
to be vaccinated if the employee or parent did not choose “not eligible” as 
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the reason why someone was not vaccinated. This assumption resulted in 
half of respondents being classified as eligible for HPV vaccination. It is 
possible that age-eligible respondents were more likely to respond to the 
survey or those respondents who were not in fact eligible for HPV 
vaccination chose other reasons for not being vaccinated and were 
incorrectly classified as eligible for vaccination. Furthermore, the response 
to the survey questions pertaining to reasons for not completing the vaccine 
series included the option “wasn’t eligible (born before 1980),” which would 
only apply to girls since the vaccine was not available for boys until 2010 
(questions 9, 10, 12, and 15). Therefore, this could result in misclassification 
of men (or sons) because they in fact were not eligible if they were born 
before 1984. Despite these limitations, the vaccination rates were 
approximately equivalent to population rates previously reported for 
Houston, and reasons for not vaccinating corresponded to those reported 
in larger population-based studies.  
 
Future directions 
 
Hospitals and other health care organizations have an opportunity to be 
leaders in workplace health promotion by adopting policies that not only 
benefit the health and well-being of their employees but also serve as role 
models for the community. Moreover, health care workers are often a main 
source of health information for the public and should therefore be 
knowledgeable about issues pertaining to public health. Literature exists 
regarding the safety and efficacy of the vaccine; however, new methods and 
platforms regarding education about disease prevention are needed. 
Although education is a start, it will take time and will likely not be enough.33  
We will use the results from this study to develop targeted education to 
increase our employees’ knowledge regarding HPV vaccination. 
 
CONCLUSION 
 
Opportunities exist to educate health care workers about the benefits of the 
HPV vaccine and to increase the number of providers who recommend HPV 
vaccination to their patients. 
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APPENDIX 
HPV Vaccine Survey 
1. What is your employee classification?  
a. Faculty 
b. Administrative 
c. Classified 
d. Student/Trainee 
 
2. Are you a health-care provider? 
a. Yes 
b. No 
If no, skip to Q5 
3. What is your classification? 
a. Physician  
b. Physician assistant or nurse practitioner  
c. Nursing 
d. Social worker/case manager 
e. Other ________ 
 
4. Do you care for pediatric patients (age <18 years) at least 25% of the 
time? 
a. Yes 
b. No 
 
5. What is your gender? 
a. Male 
b. Female 
 
6. The HPV vaccine series is covered by almost all insurance companies 
including those in the Affordable Care Act (Obama Care). Did you know 
this? 
a. Yes 
b. No 
 
7. The HPV vaccine series is covered by the vaccines for eligible children 
program for children under age 18. Did you know this? 
a. Yes 
b. No 
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8. The HPV vaccine series is covered for uninsured eligible individuals 
between ages 18-26 under the adult safety net program and can be 
given at clinics like Legacy Mapleridge Clinic, Good Neighbor 
Healthcare Center, Hope Clinic in Houston. Did you know this? 
a. Yes 
b. No 
 
9. Have you been vaccinated for HPV (completed the 3-dose series)? 
a. Yes 
b. No 
Reason 
o Started but never finished 
o Wasn’t eligible (born before 1980) 
o Didn’t know I needed it 
o Safety concerns 
o Health care provider did not recommend it 
o Don’t have enough information about the vaccine  
o Not sexually active 
o Didn’t know it was covered by my insurance 
o Other ______ 
 
10. Has your spouse/partner been vaccinated for HPV? 
a. Yes 
b. No 
Reason 
o Started but never finished 
o Wasn’t eligible (born before 1980) 
o Didn’t know they needed it 
o Safety concerns 
o Health care provider did not recommend it 
o Don’t have a spouse/partner 
o Don’t have enough information about the vaccine 
o Not sexually active 
o Didn’t know it was covered by insurance 
o Other ______ 
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11. Do you have any children? 
a. Yes, one or more daughters 
b. Yes, one or more sons 
c. Yes, both daughters and sons 
d. No, I don’t have any children 
If no, please stop here. 
The next few questions will be about your daughters, starting with your 
oldest. 
12. Has your oldest daughter been vaccinated for HPV? 
a. Yes 
b. No 
Reason 
o Started but never finished 
o Wasn’t eligible (born before 1980 or after 2005) 
o Didn’t know she needed it 
o Safety concerns 
o Pediatrician did not recommend it 
o Don’t have enough information about the vaccine 
o She is not sexually active  
o Didn’t know it was covered by my insurance 
o Other ______ 
o Not applicable 
 
13. If your daughter is too young to be vaccinated, do you plan to have her 
vaccinated when she is old enough? 
a. Yes 
b. No 
 
14. Do you have any more daughters? 
a. Yes 
b. No 
The next few questions will be about your sons, starting with your oldest. 
 
15. Has your oldest son been vaccinated for HPV? 
a. Yes 
b. No 
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Reason 
o Started but never finished 
o Wasn’t eligible (born before 1980 or after 2005) 
o Didn’t know he needed it 
o Safety concerns 
o Pediatrician did not recommend it 
o Don’t have enough information about the vaccine 
o He is not sexually active 
o Didn’t know it was covered by my insurance 
o Other ______ 
o Not applicable 
 
16. If your son is too young to be vaccinated, do you plan to have him 
vaccinated when he is old enough? 
a. Yes 
b. No 
 
17. Do you have any more sons? 
a. Yes 
b. No 
 
18. Would you bring your children to get the HPV vaccine series at the 
institution on a Saturday? 
a. Yes 
b. No 
Why not? _____________ 
c. Not applicable 
19. If you have children that are eligible for the HPV vaccine but have not 
gotten them vaccinated, what would make you more likely to get your 
child vaccinated? __________________ 
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